基本信息 产品详情 公司简介 推荐产品
  • 首页
  • 个人中心
  • 委托采购
  • 采购清单
网站主页 (BETAR)-BETA-环戊基-4-(7H-吡咯并[2,3-D]嘧啶-4-基)-1H-吡唑-1-丙腈硫酸盐 化合物 Ruxolitinib sulfate
  • 化合物 Ruxolitinib sulfate|T61988|TargetMol

化合物 Ruxolitinib sulfate|T61988|TargetMol

Ruxolitinib sulfate
1092939-16-6
￥17500 100mg 起订
￥13800 50mg 起订
￥10600 25mg 起订
上海 更新日期：2024-09-30

TargetMol中国（陶术生物）

VIP3年
联系人：邵小姐
手机：4008200310 拨打
邮箱：marketing@tsbiochem.com

产品详情:

中文名称：
化合物 Ruxolitinib sulfate
英文名称：
Ruxolitinib sulfate
CAS号：
1092939-16-6
品牌：
TargetMol
产地：
美国
保存条件：
Shipping with blue ice.
产品类别：
抑制剂
货号：
T61988

Product Introduction

Bioactivity

NameRuxolitinib sulfate
DescriptionRuxolitinib sulfate (INCB018424 sulfate) is a potent, selective JAK1/2 inhibitor with IC 50 s of 3.3 nM/2.8 nM. Ruxolitinib sulfate shows > 130-fold selectivity for JAK1/2 versus JAK3.
In vitroRuxolitinib sulfate (INCB018424 sulfate) potently and selectively inhibits JAK2V617F-mediated signaling and proliferation, markedly increases apoptosis in a dose dependent manner, and at 64 nM results in a doubling of cells with depolarized mitochondria in Ba/F3 cells. Ruxolitinib demonstrates remarkable potency against erythroid colony formation with IC 50 of 67 nM, and inhibits proliferating of erythroid progenitors from normal donors and polycythemia vera patients with IC 50 values of 407 nM and 223 nM, respectively [1].
In vivoRuxolitinib (INCB018424 sulfate; 180 mg/kg, orally, twice a day) results in survive rate of greater than 90% by day 22 and markedly reduces splenomegaly and circulating levels of inflammatory cytokines, and preferentially eliminated neoplastic cells, resulting in significantly prolonged survival without myelosuppressive or immunosuppressive effects in a JAK2V617F-driven mouse model [1]. In the Ruxolitinib group, the primary end point is reached in 41.9% of patients, as compared with 0.7% in the placebo group in the double-blind trial of myelofibrosis. Ruxolitinib results in maintaining of reduction in spleen volume and improvement of 50% or more in the total symptom score [2]. Ruxolitinib (15 mg twice daily) treatment leads a total of 28% of the patients to have at least a 35% reduction in spleen volume at week 48 in patients with myelofibrosis, as compared with 0% in the group receiving the best available therapy. The mean palpable spleen length has decreased by 56% with Ruxolitinib but has increased by 4% with the best available therapy at week 48. Patients in the ruxolitinib group has an improvement in overall quality-of-life measures and a reduction in symptoms associated with myelofibrosis [3].
StorageShipping with blue ice.
Ruxolitinib sulfate|TargetMol

公司简介

TargetMol Chemicals Inc. 总部位于马萨诸塞州波士顿，致力于为全球生化领域科学家的研究提供专业的产品和服务。TargetMol?品牌的客户群分布于40多个国家和地区，已发展成为全球知名的化合物库和小分子化合物研究供应商。 TargetMol?可提供160多种满足不同需求的化合物库，以及多种类型的生化试剂产品，包括12000多种抑制剂、16000多种天然产物和各类多肽、抗体、生命科学试剂盒等，此外，我们还建设有CADD（计算机辅助药物设计）研究中心、药理实验室、药化合成平台三大技术中心，全方位满足客户的定制需求。 凭借我们优质的产品和服务、快速高效的全球供应链和专业的技术支持，我们将有效帮助您缩短研发周期，取得更成功的结果。

成立日期 (12年)
注册资本 566.265100万人民币
员工人数 100-500人
年营业额 ￥ 1亿以上
经营模式 贸易,工厂,试剂,定制,服务
主营行业 天然产物,生化试剂,分子生物学,分子砌块,生物技术服务

化合物 Ruxolitinib sulfate相关厂家报价

  • Ruxolitinib
  • Ruxolitinib
  • 上海厚博生物科技有限公司 VIP
  • 2024-08-09
  • 询价
内容声明
official 进入官方账号
拨打电话 立即询价